L04AA26 • belimumab • Antineoplastic and immunomodulating agents | Immunosuppressants | Selective immunosuppressants
Belimumabum is a medication used for the treatment of active systemic lupus erythematosus (SLE), particularly in adult patients with positive autoantibodies. It is a monoclonal antibody that inhibits the BLyS protein (B-lymphocyte stimulator), reducing the activity of abnormal B-lymphocytes involved in the autoimmune process.
The medication is administered via intravenous infusion or subcutaneous injection, as directed by a doctor. The dosage and frequency are adjusted based on the patient's response.
Common side effects include nausea, diarrhea, fever, respiratory infections, and injection site reactions. In rare cases, more severe adverse effects such as depression, suicidal thoughts, or severe infections may occur.
Belimumabum is not recommended for pregnant or breastfeeding women unless the benefits outweigh the risks. Patients should inform their doctor about all medications they are taking to avoid drug interactions.
Substance: belimumab
Date of last drug list: 01-02-2018
Commercial code: W64070001
Concentration: 200mg
Pharmaceutical form: solution for injection in pre-filled syringe
Quantity: 1
Product type: original
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).